IMpower010 [22] was a phase III randomized trial testing the Programmed Death-Ligand 1 (PD-L1) inhibitor atezolizumab at 1200 mg every 21 days for one year vs. the best supportive care, in patients with resected stage IB to IIIA NSCLC (AJCC Staging Manual, 7th edition) who had received adjuvant platinum doublet-based chemotherapy for 1–4 cycles after surgery. Here, CD274 is linked to non-small cell lung carcinoma.